Research Article
BibTex RIS Cite

Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS

Year 2021, Volume: 23 Issue: 3, 276 - 281, 30.12.2021

Deren Tokmak Ferhat Şirinyıldız Rauf Onur Ek

https://doi.org/10.18678/dtfd.991389

Abstract

Aim: In this study, it was aimed to investigate the effects of beta glucan (BG) on the experimental colitis model created by using trinitrobenzene sulfonic acid (TNBS).
Material and Methods: Thirty-two Wistar Albino rats were divided equally into four groups as sham control, TNBS, TNBS-BG3, and TNBS-BG10 groups. While saline was administrated to sham group, TNBS was administered intrarectally to the TNBS groups under anesthesia. BG was administered at a dose of 100 mg/kg by oral gavage, intragastrically, for 3 days (TNBS+3) to the TNBS-BG3 group and for 10 days (7+TNBS+3) to the TNBS-BG10 group. At the end of the study, macroscopic, histological and biochemical tests were applied to the colon tissues taken.
Results: It was determined by histopathological scoring and biochemical results that BG administration caused positive effects on colon damage due to colitis. Malondialdehyde level and myeloperoxidase activity were found to be significantly higher in the TNBS group compared to the other groups (p=0.003 and p<0.001, respectively). Antioxidant levels increased in BG treated groups compared to TNBS group. While this increase was statistically significant among glutathione levels (p<0.001), it was not statistically significant in catalase enzyme activity (p=0.218). BG administration reduced the increase in lipid peroxidation and leukocyte infiltration level in the colon tissue. Positive changes due to the prophylactic effect of BG were determined in histological and biochemical results.
Conclusion: BG administration has been found to show anti-inflammatory and antioxidant properties, and BG has a treatment potential in reducing colon tissue damage due to TNBS-induced colitis.

Keywords

Anti-inflammatory Antioxidant Beta glucan Ulcerative colitis

Supporting Institution

Aydin Adnan Menderes University, Scientific Research Projects Committee

Project Number

TPF-13021

References

  • Petronis A, Petroniene R. Epigenetics of inflammatory bowel disease. Gut. 2000;47(2):302-6.
  • Gasche C, Scholmerich J, Brynskov J, D’Haens G, Hanauer SB, Irvine EJ, et al. A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6(1):8-15.
  • Norris AA, Lewis AJ, Zeitlin IJ. Changes in colonic tissue levels of inflammatory mediators in a guinea-pig model of immune colitis. Agents Actions. 1982;12(1-2):243-6.
  • Selve N. Chronic intrajejunal TNBS application in TNBS-sensitized rats: a new model of chronic inflammatory bowel diseases. Agents Actions. 1992;Spec No:C15-7.
  • Podolsky D. Inflamatory bowel disease. N Engl J Med. 2002;347(6):417-29.
  • Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 2012;380(9853):1606-19.
  • Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573-621.
  • Grisham MB, Granger DN. Neutrophil-mediated mucosal injury. Role of reactive oxygen metabolites. Dig Dis Sci. 1988;33(3 Suppl):6S-15S.
  • Campbell-Thomson M, Lynch IJ, Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ER beta isoforms in colon cancer. Cancer Res. 2001;61(2):632-40.
  • Konstantinopoulos PA, Kominea A, Vandoros G, Sykiotis GP, Andricopoulos P, Varakis I, et al. Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour’s dedifferentiation. Eur J Cancer. 2003;39(9):1251-8.
  • Wada-Hiraike O, Warner M, Gustafsson JA. New developments in oestrogen signalling in colonic epithelium. Biochem Soc Trans. 2006;34(Pt 6):1114-6.
  • Girgin F, Karaoglu O, Erkuş M, Tüzün S, Ozütemiz O, Dinçer C, et al. Effects of trimetazidine on oxidant⁄antioxidant statusin trinitrobenzenesulfonic acid-induced chronic colitis. J Toxicol Environ Health. 2000;59(8):641-52.
  • Kim SY, Song HJ, Lee YY, Cho KH, Roh YK. Biomedical Issues of dietary fiber beta-glucan. J Korean Med Sci. 2006;21(5):781-9.
  • Zeković DB, Kwiatkowski S, Vrvić MM, Jakovljević D, Moran CA. Natural and modified (1-->3)-beta-D-glucans in health promotion and disease alleviation. Crit Rev Biotechnol. 2005;25(4):205-30.
  • Şener M, Canda E, Gürel D. Effects of enteral beta glucan in a rat model of short bowel on intestinal adaptation. Genel Tıp Derg. 2011;21(3):95-9. Turkish.
  • Bayrak O, Turgut F, Karatas OF, Cimentepe E, Bayrak R, Catal F, et al. Oral beta-glucan protects kidney against ischemia/reperfusion injury in rats. Am J Nephrol. 2008;28(2):190-6.
  • Wei D, Zhang L, Williams DL, Browder IW. Glucan stimulates human dermal fibroblast collagen biosynthesis through a nuclear factor-1 dependent mechanism. Wound Repair Regen. 2002;10(3):161-8.
  • González R, Rodríguez S, Romay C, Ancheta O, González A, Armesto J, et al. Anti-inflammatory activity of phycocyanin extract in acetic acid-induced colitis in rats. Pharmacol Res. 1999;39(1):55-9.
  • Jurjus AR, Khoury NN, Reimund JM. Animal models of inflammatory bowel disease. J Pharmacol Toxicol Methods. 2004;50(2):81-92.
  • Millar AD, Rampton DS, Chander CL, Claxson AW, Blades S, Coumbe A, et al. Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis. Gut. 1996;39(3):407-15.
  • Xue NN, He M, Li Y, Wu JZ, Du WW, Wu XM, et al. Periplaneta americana extract promotes intestinal mucosa repair of ulcerative colitis in rat. Acta Cir Bras. 2020;35(10):e202001002.
  • Shanmugam S, Thangaraj P, Dos Santos Lima B, Trindade GGG, Narain N, Mara de Oliveira E Silva A, et al. Protective effects of flavonoid composition rich P. subpeltata Ortega. on indomethacin induced experimental ulcerative colitis in rat models of inflammatory bowel diseases. J Ethnopharmacol. 2020;248:112350.
  • Motawea MH, Abd Elmaksoud HA, Elharrif MG, Desoky AAE, Ibrahimi A. Evaluation of anti-inflammatory and antioxidant profile of oleuropein in experimentally induced ulcerative colitis. Int J Mol Cell Med. 2020;9(3):224-33.
  • Guazelli CFS, Fattori V, Ferraz CR, Borghi SM, Casagrande R, Baracat MM, et al. Antioxidant and anti-inflammatory effects of hesperidin methyl chalcone in experimental ulcerative colitis. Chem Biol Interact. 2021;333:109315.
  • Nosál'ová V, Cerná S, Bauer V. Effect of N-acetylcysteine on colitis induced by acetic acid in rats, Gen Pharmacol. 2000;35(2):77-81.
  • Ademoglu E, Erbil Y, Tam B, Barbaros U, Ilhan E, Olgac V, et al. Do vitamin E and selenium have beneficial effects on trinitrobenzenesulfonic acid-induced experimental colitis. Dig Dis Sci. 2004;49(1):102-8.
  • Ek RO, Serter M, Ergin K, Yildiz Y, Cecen S, Kavak T, et al. The effects of caffeic acid phenethyl ester (CAPE) on TNBS-induced colitis in ovariectomized rats. Dig Dis Sci. 2008;53(6):1609-17.
  • Ige SF, Adeniyi MJ, Olayinka AT, Kehinde IC. Role of dietary maize formulations in the healing of experimental acetic acid induced ulcerative colitis in male rats. Chin J Physiol. 2020;63(4):156-62.
  • Karabeyoglu SM, Bozkurt B, Unal B, Yilmaz OC, Bilgihan A, Atasay FO, et al. Results of ethyl pyruvate application in an experimental colitis model. Visc Med. 2008;24(2):162-6.
  • Kuralay F, Yildiz C, Ozutemiz O, Islekel H, Caliskan S, Bingol B, et al. Effects of trimetazidine on acetic acid-induced colitis in female Swiss rats. J Toxicol Environ Health A. 2003;66(2):169-79.
  • Yildiz G, Yildiz Y, Ulutas PA, Yaylali A, Ural M. Resveratrol pretreatment ameliorates TNBS colitis in rats. Recent Pat Endocr Metab Immune Drug Discov. 2015;9(2):134-40.
  • Sener G, Toklu H, Ercan F, Erkanli G. Protective effect of beta-glucan against oxidative organ injury in a rat model of sepsis. Int Immunopharmacol. 2005;5(9):1387-96.
  • Kayali H, Ozdag MF, Kahraman S, Aydin A, Gonol E, Sayal A, et al. The antioksidant effect of beta-glucan on oxidative stress status in experimental spinal cord injury in rats. Neurosurg Rev. 2005;28(4):298-302.
  • Sener G, Toklu HZ, Cetinel S. β-Glucan protects against chronic nicotine-induced oxidative damage in rat kidney and bladder. Environ Toxicol Pharmacol. 2007;23(1):25-32.
  • Tatli Seven P, Iflazoglu Mutlu S, Seven I, Arkali G, Ozer Kaya S, Kanmaz OE. Protective role of yeast beta-glucan on lead acetate-induced hepatic and reproductive toxicity in rats. Environ Sci Pollut Res. 2021;28(38):53668-78.

TNBS ile Oluşturulan Deneysel Ülseratif Kolit Modelinde Beta Glukan Uygulamasının Koruyucu ve Terapötik Etkileri

Year 2021, Volume: 23 Issue: 3, 276 - 281, 30.12.2021

Deren Tokmak Ferhat Şirinyıldız Rauf Onur Ek

https://doi.org/10.18678/dtfd.991389

Abstract

Amaç: Bu çalışmada trinitrobenzen sülfonik asit (TNBS) kullanılarak oluşturulan deneysel kolit modeli üzerinde beta glukan (BG)’ın etkilerinin araştırılması amaçlanmıştır.
Gereç ve Yöntemler: Otuz iki Wistar Albino sıçan eşit olarak sham kontrol, TNBS, TNBS-BG3 ve TNBS-BG10 gruplarına ayrılmıştır. Sham grubuna serum fizyolojik uygulanırken, TNBS gruplarına anestezi altında intrarektal yol ile TNBS uygulanmıştır. BG 100 mg/kg dozunda, TNBS-BG3 grubuna 3 gün (TNBS+3) süreyle, TNBS-BG10 grubuna ise 10 gün (7+TNBS+3) süreyle, intragastrik şekilde oral gavaj yolu ile verilmiştir. Çalışmanın sonunda alınan kolon dokularına makroskobik, histolojik ve biyokimyasal testler uygulanmıştır.
Bulgular: BG uygulamasının kolite bağlı kolon hasarında olumlu etkilere neden olduğu, histopatolojik skorlama ve biyokimyasal sonuçlar ile tespit edilmiştir. Malondialdehid seviyesi ve miyeloperoksidaz aktivitesinin diğer gruplar ile karşılaştırıldığında TNBS grubunda, anlamlı derecede yüksek olduğu tespit edilmiştir (sırasıyla p=0,003 ve p<0.001). BG tedavisi uygulanan gruplarda, antioksidan düzeyi TNBS grubuna göre artış göstermiştir. Bu artış glutatyon düzeyleri arasında istatistiksel olarak anlamlı iken (p<0.001), katalaz enzim aktivitesinde istatistiksel olarak anlamlılık ortaya çıkmamıştır (p=0.218). BG uygulaması, kolon dokusundaki lipit peroksidasyon ve lökosit infiltrasyon düzeyindeki artışı azaltmıştır. Histolojik ve biyokimyasal sonuçlarda BG’nin profilaktik etkisine bağlı olarak olumlu değişiklikler tespit edilmiştir.
Sonuç: BG uygulamasının anti-inflamatuar ve antioksidan özellikler gösterdiği tespit edilmiştir ve TNBS ile indüklenen kolit sonucu oluşan kolon doku hasarını azaltmada BG tedavi edici potansiyel taşımaktadır.

Keywords

Anti-inflamatuar Antioksidan Beta glukan Ülseratif kolit

Project Number

TPF-13021

References

  • Petronis A, Petroniene R. Epigenetics of inflammatory bowel disease. Gut. 2000;47(2):302-6.
  • Gasche C, Scholmerich J, Brynskov J, D’Haens G, Hanauer SB, Irvine EJ, et al. A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis. 2000;6(1):8-15.
  • Norris AA, Lewis AJ, Zeitlin IJ. Changes in colonic tissue levels of inflammatory mediators in a guinea-pig model of immune colitis. Agents Actions. 1982;12(1-2):243-6.
  • Selve N. Chronic intrajejunal TNBS application in TNBS-sensitized rats: a new model of chronic inflammatory bowel diseases. Agents Actions. 1992;Spec No:C15-7.
  • Podolsky D. Inflamatory bowel disease. N Engl J Med. 2002;347(6):417-29.
  • Ordás I, Eckmann L, Talamini M, Baumgart DC, Sandborn WJ. Ulcerative colitis. Lancet 2012;380(9853):1606-19.
  • Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573-621.
  • Grisham MB, Granger DN. Neutrophil-mediated mucosal injury. Role of reactive oxygen metabolites. Dig Dis Sci. 1988;33(3 Suppl):6S-15S.
  • Campbell-Thomson M, Lynch IJ, Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ER beta isoforms in colon cancer. Cancer Res. 2001;61(2):632-40.
  • Konstantinopoulos PA, Kominea A, Vandoros G, Sykiotis GP, Andricopoulos P, Varakis I, et al. Oestrogen receptor beta (ERbeta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour’s dedifferentiation. Eur J Cancer. 2003;39(9):1251-8.
  • Wada-Hiraike O, Warner M, Gustafsson JA. New developments in oestrogen signalling in colonic epithelium. Biochem Soc Trans. 2006;34(Pt 6):1114-6.
  • Girgin F, Karaoglu O, Erkuş M, Tüzün S, Ozütemiz O, Dinçer C, et al. Effects of trimetazidine on oxidant⁄antioxidant statusin trinitrobenzenesulfonic acid-induced chronic colitis. J Toxicol Environ Health. 2000;59(8):641-52.
  • Kim SY, Song HJ, Lee YY, Cho KH, Roh YK. Biomedical Issues of dietary fiber beta-glucan. J Korean Med Sci. 2006;21(5):781-9.
  • Zeković DB, Kwiatkowski S, Vrvić MM, Jakovljević D, Moran CA. Natural and modified (1-->3)-beta-D-glucans in health promotion and disease alleviation. Crit Rev Biotechnol. 2005;25(4):205-30.
  • Şener M, Canda E, Gürel D. Effects of enteral beta glucan in a rat model of short bowel on intestinal adaptation. Genel Tıp Derg. 2011;21(3):95-9. Turkish.
  • Bayrak O, Turgut F, Karatas OF, Cimentepe E, Bayrak R, Catal F, et al. Oral beta-glucan protects kidney against ischemia/reperfusion injury in rats. Am J Nephrol. 2008;28(2):190-6.
  • Wei D, Zhang L, Williams DL, Browder IW. Glucan stimulates human dermal fibroblast collagen biosynthesis through a nuclear factor-1 dependent mechanism. Wound Repair Regen. 2002;10(3):161-8.
  • González R, Rodríguez S, Romay C, Ancheta O, González A, Armesto J, et al. Anti-inflammatory activity of phycocyanin extract in acetic acid-induced colitis in rats. Pharmacol Res. 1999;39(1):55-9.
  • Jurjus AR, Khoury NN, Reimund JM. Animal models of inflammatory bowel disease. J Pharmacol Toxicol Methods. 2004;50(2):81-92.
  • Millar AD, Rampton DS, Chander CL, Claxson AW, Blades S, Coumbe A, et al. Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis. Gut. 1996;39(3):407-15.
  • Xue NN, He M, Li Y, Wu JZ, Du WW, Wu XM, et al. Periplaneta americana extract promotes intestinal mucosa repair of ulcerative colitis in rat. Acta Cir Bras. 2020;35(10):e202001002.
  • Shanmugam S, Thangaraj P, Dos Santos Lima B, Trindade GGG, Narain N, Mara de Oliveira E Silva A, et al. Protective effects of flavonoid composition rich P. subpeltata Ortega. on indomethacin induced experimental ulcerative colitis in rat models of inflammatory bowel diseases. J Ethnopharmacol. 2020;248:112350.
  • Motawea MH, Abd Elmaksoud HA, Elharrif MG, Desoky AAE, Ibrahimi A. Evaluation of anti-inflammatory and antioxidant profile of oleuropein in experimentally induced ulcerative colitis. Int J Mol Cell Med. 2020;9(3):224-33.
  • Guazelli CFS, Fattori V, Ferraz CR, Borghi SM, Casagrande R, Baracat MM, et al. Antioxidant and anti-inflammatory effects of hesperidin methyl chalcone in experimental ulcerative colitis. Chem Biol Interact. 2021;333:109315.
  • Nosál'ová V, Cerná S, Bauer V. Effect of N-acetylcysteine on colitis induced by acetic acid in rats, Gen Pharmacol. 2000;35(2):77-81.
  • Ademoglu E, Erbil Y, Tam B, Barbaros U, Ilhan E, Olgac V, et al. Do vitamin E and selenium have beneficial effects on trinitrobenzenesulfonic acid-induced experimental colitis. Dig Dis Sci. 2004;49(1):102-8.
  • Ek RO, Serter M, Ergin K, Yildiz Y, Cecen S, Kavak T, et al. The effects of caffeic acid phenethyl ester (CAPE) on TNBS-induced colitis in ovariectomized rats. Dig Dis Sci. 2008;53(6):1609-17.
  • Ige SF, Adeniyi MJ, Olayinka AT, Kehinde IC. Role of dietary maize formulations in the healing of experimental acetic acid induced ulcerative colitis in male rats. Chin J Physiol. 2020;63(4):156-62.
  • Karabeyoglu SM, Bozkurt B, Unal B, Yilmaz OC, Bilgihan A, Atasay FO, et al. Results of ethyl pyruvate application in an experimental colitis model. Visc Med. 2008;24(2):162-6.
  • Kuralay F, Yildiz C, Ozutemiz O, Islekel H, Caliskan S, Bingol B, et al. Effects of trimetazidine on acetic acid-induced colitis in female Swiss rats. J Toxicol Environ Health A. 2003;66(2):169-79.
  • Yildiz G, Yildiz Y, Ulutas PA, Yaylali A, Ural M. Resveratrol pretreatment ameliorates TNBS colitis in rats. Recent Pat Endocr Metab Immune Drug Discov. 2015;9(2):134-40.
  • Sener G, Toklu H, Ercan F, Erkanli G. Protective effect of beta-glucan against oxidative organ injury in a rat model of sepsis. Int Immunopharmacol. 2005;5(9):1387-96.
  • Kayali H, Ozdag MF, Kahraman S, Aydin A, Gonol E, Sayal A, et al. The antioksidant effect of beta-glucan on oxidative stress status in experimental spinal cord injury in rats. Neurosurg Rev. 2005;28(4):298-302.
  • Sener G, Toklu HZ, Cetinel S. β-Glucan protects against chronic nicotine-induced oxidative damage in rat kidney and bladder. Environ Toxicol Pharmacol. 2007;23(1):25-32.
  • Tatli Seven P, Iflazoglu Mutlu S, Seven I, Arkali G, Ozer Kaya S, Kanmaz OE. Protective role of yeast beta-glucan on lead acetate-induced hepatic and reproductive toxicity in rats. Environ Sci Pollut Res. 2021;28(38):53668-78.
There are 35 citations in total.

Details

Primary Language English
Subjects Clinical Sciences
Journal Section Research Article
Authors

Deren Tokmak 0000-0002-7953-8684

Ferhat Şirinyıldız 0000-0001-8800-9787

Rauf Onur Ek 0000-0003-3923-0156

Project Number TPF-13021
Publication Date December 30, 2021
Submission Date September 5, 2021
Published in Issue Year 2021 Volume: 23 Issue: 3

Cite

APA Tokmak, D., Şirinyıldız, F., & Ek, R. O. (2021). Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS. Duzce Medical Journal, 23(3), 276-281. https://doi.org/10.18678/dtfd.991389
AMA Tokmak D, Şirinyıldız F, Ek RO. Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS. Duzce Med J. December 2021;23(3):276-281. doi:10.18678/dtfd.991389
Chicago Tokmak, Deren, Ferhat Şirinyıldız, and Rauf Onur Ek. “Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS”. Duzce Medical Journal 23, no. 3 (December 2021): 276-81. https://doi.org/10.18678/dtfd.991389.
EndNote Tokmak D, Şirinyıldız F, Ek RO (December 1, 2021) Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS. Duzce Medical Journal 23 3 276–281.
IEEE D. Tokmak, F. Şirinyıldız, and R. O. Ek, “Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS”, Duzce Med J, vol. 23, no. 3, pp. 276–281, 2021, doi: 10.18678/dtfd.991389.
ISNAD Tokmak, Deren et al. “Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS”. Duzce Medical Journal 23/3 (December 2021), 276-281. https://doi.org/10.18678/dtfd.991389.
JAMA Tokmak D, Şirinyıldız F, Ek RO. Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS. Duzce Med J. 2021;23:276–281.
MLA Tokmak, Deren et al. “Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS”. Duzce Medical Journal, vol. 23, no. 3, 2021, pp. 276-81, doi:10.18678/dtfd.991389.
Vancouver Tokmak D, Şirinyıldız F, Ek RO. Protective and Therapeutic Effects of Beta Glucan Administration on Experimental Ulcerative Colitis Model Induced by TNBS. Duzce Med J. 2021;23(3):276-81.
 Download Cover Image
Creative Commons License
Duzce Medical Journal is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.